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Summary
Treatment benefit in multiple myeloma (MM) patients with high-risk cyto-
genetics remains suboptimal. The phase 3 ICARIA-MM trial
(NCT02990338) showed that isatuximab plus pomalidomide–dexametha-
sone prolongs median progression-free survival (mPFS) in patients with
relapsed/refractory MM (RRMM). This subgroup analysis of ICARIA-MM
compared the benefit of isatuximab in high-risk [defined by the presence
of del(17p), t(4;14) or t(14;16)] versus standard-risk patients. The efficacy
of isatuximab in patients with gain(1q21) abnormality was also assessed in
a retrospective subgroup analysis. In ICARIA-MM, 307 patients received
isatuximab–pomalidomide–dexamethasone (n = 154) or pomalidomide–
dexamethasone (n = 153). Isatuximab (10 mg/kg intravenously) was given
weekly in the first 28-day cycle, and every other week thereafter. Standard
pomalidomide–dexamethasone doses were given. Isatuximab–pomalido-
mide–dexamethasone improved mPFS (75 vs 37 months; HR, 066; 95%
CI, 033–128) and overall response rate (ORR, 500% vs 167%) in high-
risk patients. In patients with isolated gain(1q21), isatuximab addition
improved mPFS (112 vs 46 months; HR, 050; 95% CI, 028–088) and
ORR (536% vs 276%). More grade ≥3 adverse events occurred in high-
risk patients receiving isatuximab (957%) versus the control group
(676%); however, isatuximab did not increase events leading to discontin-
uation or treatment-related mortality. Isatuximab–pomalidomide–dexam-
ethasone provides a consistent benefit over pomalidomide–dexamethasone
treatment in RRMM patients regardless of cytogenetic risk.
Keywords: cytogenetics, gain (1q21), high-risk, isatuximab, relapsed/refrac-
tory multiple myeloma.
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Introduction
Multiple myeloma (MM) is a haematological malignancy
characterised by abnormal proliferation of plasma cells in
the bone marrow, thereby leading to bone destruction and
marrow failure. It is a heterogeneous disease with variable
prognosis depending on host factors such as age/frailty and
renal failure, disease burden and tumour biology, high-risk
cytogenetics and prior therapies.1 Despite recent advances
in the treatment of MM, relapse is inevitable and the dis-
ease is considered incurable with current treatment
approaches.
Risk classification based on cytogenetic profiling, and care-
ful analysis of risk subgroups is becoming increasingly
important in the evaluation of novel therapies.2 The Revised
International Staging System (R-ISS) for MM defines patients
with del(17p), and/or t(4;14), and/or t(14;16) abnormalities
as high-risk.3,4 Importantly, high-risk patients have a median
overall survival (OS) of only three years versus 10 years in
low-risk patients.1 Additionally, gain(1q21), one of the most
common chromosomal abnormalities in MM, occurs in 20–
50% of newly diagnosed patients with increased incidence in
relapsed/refractory multiple myeloma (RRMM),5 and has
been linked with inferior outcomes.6-10
Novel agents such as immunomodulatory (IMiD) drugs
and proteasome inhibitors have led to higher response rates
and lower toxicity than standard, non-specific chemotherapy
in patients with MM.11 Pomalidomide is a second-
generation IMiD, which, in combination with low-dose dex-
amethasone, is approved for the treatment of RRMM in
patients who previously received ≥2 lines of therapy, includ-
ing lenalidomide and a proteasome inhibitor.12 Pomalido-
mide plus low-dose dexamethasone compared with high-
dose dexamethasone improved progression-free survival
(PFS) in patients with RRMM who had the high-risk abnor-
malities del(17p) [46 vs 11 months; hazard ratio (HR),
034; P < 0001] and t(4;14) (28 vs 19 months; HR, 049;
P = 0028).13 While pomalidomide and other novel agents
have extended the OS of MM patients, those who fail these
regimens have a poor prognosis, warranting the need for
new treatments.11
Among emerging therapies for MM, monoclonal antibod-
ies targeting the CD38 receptor (expressed at high levels on
malignant MM cells) represent an important class of drugs
against this disease. Isatuximab, an IgG1 monoclonal anti-
body, binds to a different epitope on the CD38 receptor than
other clinically available anti-CD38 antibodies and mediates
tumour cell death via multiple mechanisms.14-16
In the phase 3 ICARIA-MM study involving 307 patients
with RRMM, isatuximab plus pomalidomide and low-dose
dexamethasone significantly improved PFS [115 vs
65 months; HR, 0596; 95% confidence interval (CI), 044–
081; P = 0001], overall response rate (ORR, 60% vs 35%),
and the depth of response compared with pomalidomide–dex-
amethasone.17 This study met its primary end-point and
formed the basis for the approval of isatuximab plus poma-
lidomide–dexamethasone for the treatment of adult patients
with RRMM who received ≥2 prior therapies, including
lenalidomide and a proteasome inhibitor. Furthermore, based
on the phase 3 IKEMA study, on February 26, 2021, the Com-
mittee for Medicinal Products for Human Use (CHMP) issued
a positive opinion for a second indication for isatuximab, in
combination with carfilzomib and dexamethasone for adult
patients with MM who have received at least one prior ther-
apy. In this prespecified subgroup analysis of ICARIA-MM
(NCT02990338), we evaluated the efficacy and safety of isatux-
imab plus pomalidomide–dexamethasone treatment in high-
risk versus standard-risk cytogenetic patients with RRMM. In
addition, we conducted a retrospective analysis of patient sam-
ples from ICARIA-MM to compare the efficacy of isatuximab
plus pomalidomide–dexamethasone in patients with gain
(1q21) compared with those without the abnormality.
Patients and methods
Study design and patients
The ICARIA-MM study has been previously described,11,17
and is registered at ClinicalTrials.gov, number NCT02990338.
Briefly, eligible patients had RRMM and received ≥2 prior
lines of therapy and were refractory to lenalidomide and a
proteasome inhibitor given alone or in combination. The
protocol was approved by independent ethics committees
and institutional review boards at all participating institu-
tions. All authors had full access to the study data. Written
informed consent was obtained from all patients.
Randomisation
Patients were randomly assigned in a 1:1 ratio to either isat-
uximab–pomalidomide–dexamethasone (154 patients), or
pomalidomide–dexamethasone (153). Randomisation was
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stratified based on the number of prior lines of treatment
(2–3 vs >3) and age (<75 vs ≥75 years).
Procedures
As described previously, patients in the isatuximab–poma-
lidomide–dexamethasone group received 10 mg/kg isatux-
imab intravenously (on days 1, 8, 15 and 22 in the first 28-
day cycle, and days 1 and 15 in subsequent cycles) plus
pomalidomide (4 mg orally on days 1 to 21 in each cycle)
plus dexamethasone (40 mg orally or intravenously on days
1, 8, 15 and 22 in each cycle; 20 mg for ≥75 years old).
Pomalidomide and dexamethasone were administered on the
same schedule in all patients.
Outcomes
The primary end-point of the ICARIA-MM study was PFS.
Secondary end-points included the ORR, OS and safety. Data
on OS was not yet mature at the time of this analysis. The
end-points for this subgroup analysis are the same as in the
primary study.
In the high-risk cytogenetic population, PFS was a pre-
specified subgroup analysis. Cytogenetic risk was assessed by
central laboratory fluorescence in situ hybridisation (FISH)
testing after immunomagnetic isolation of CD138+ plasma
cells from baseline bone marrow aspirate, interphase chro-
mosome preparation, and hybridisation with Kreatech FISH
probes [11q22.3(ATM)/17p13.1(p53), 4p16.3(FGFR3);
14q32.3(IGH); 16q23.2(MAF)]. High-risk cytogenetic status
was defined by the presence of ≥1 of del(17p), t(4;14) or t
(14;16), and was considered positive if present in ≥30%
plasma cells for t(4;14) and t(14;16), and in ≥50% plasma
cells for del(17p). For sensitivity analyses, thresholds ranging
from 5% to 60% for del(17p), and 3% to 60% for t(4;14)
were used.
The gain(1q21) subgroup was evaluated in a retrospective
analysis using the remaining CD138+ plasma cells collected
for cytogenetic risk evaluation and was considered positive if
≥3 copies of 1q21 were present in ≥30% of analysed cells.
Amplification of 1q21 was also evaluated and was considered
positive if ≥4 copies of 1q21 were present in ≥30% of anal-
ysed cells.
Statistical analysis
Statistical analysis for the ICARIA-MM study has been previ-
ously described.17 All efficacy analyses were conducted in the
intent-to-treat population. For this subgroup analysis, the
HR and the associated 95% CI for the treatment effect were
estimated, and PFS was analysed using a Cox proportional
hazards model with terms for the factor, treatment and their
interaction. The test for the interaction was performed at the
10% alpha level. PFS was analysed using the Kaplan–Meier
method by treatment group with the same censoring rules as
the primary analysis, and comparisons between treatment
groups were made using a one-sided log-rank test. The
response rates were compared using the unstratified
Cochran–Mantel–Haenszel test. Sensitivity analyses were con-




Of the 307 patients recruited between 10 January 2017 and 2
February 2018 for the ICARIA-MM study,17 cytogenetic risk
was assessable by central laboratory in 241 patients (785%).
Missing results in 66 (215%) patients were because samples
were not provided or were of poor quality. Of the 241
patients with cytogenetic risk data, 60 (249%) were classified
as high risk, according to the pre-specified definitions.
Results were compared with those from standard-risk
patients (181 out of 307).
High-risk chromosomal abnormalities were present in
fewer patients in the isatuximab treatment group [24
(156%)] than in the pomalidomide–dexamethasone group
[36 (235%)], with del(17p) and t(4;14) being the most fre-
quent abnormalities in both groups (Table I).
Patient baseline characteristics and disease characteristics
divided by cytogenetic risk are shown in Table II. More
patients in the high-risk subgroup were aged ≥75 years, had
lactate dehydrogenase levels greater than the upper limit of
normal, were ISS stage III, and had an Eastern Cooperative
Oncology Group performance status of 2.
Efficacy
Response rate based on the independent response committee
assessment was determined for patients in the overall high-
risk cytogenetic population and in patients with del(17p) and
t(4;14). Among high-risk patients, the ORR was higher in
patients who received isatuximab plus pomalidomide–dex-
amethasone than those who received pomalidomide–dexam-
ethasone (500% vs 167%, P = 00031; Fig 1). This ORR
benefit was maintained regardless of whether the patient had
del(17p) (500% vs 220%) or t(4;14) (500% vs 70%;
Fig 2). Standard-risk patients had an ORR of 650% in the
isatuximab group and 423% in the pomalidomide–dexam-
ethasone group (P = 00012; Fig 1). With the addition of
isatuximab, a higher percentage of patients achieved very
good partial response (VGPR) in the high-risk subgroup
(292% vs 28%), and ≥VGPR rate in the standard-risk sub-
group (320% vs 90%). Among patients with both del(17p)
and t(4;14), one out of three patients in the isatuximab
group achieved VGPR, and one out of four patients in the
control group achieved partial response. Collectively, these
data show that the ORR benefit with isatuximab was main-
tained among patients with high-risk cytogenetics.
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A sensitivity analysis was conducted to determine whether
the ORR benefit in the high-risk subgroup was maintained
independent of the high-risk cytogenetic cut-off definition
used. Results demonstrated that the higher ORR observed
with isatuximab compared with pomalidomide–dexametha-
sone backbone was consistent across all tested thresholds for
both del(17p) as well as t(4;14) abnormalities. For del(17p),
the percentage of overall responders with isatuximab ranged
from 42% with a 5% cut-off to 50% with a 50% cut-off
(Fig 2). Increasing the threshold to 60% decreased the ORR
to 40%. The ORR in the control group ranged from 19% at
5% cut-off to 22% at 50% cut-off; increasing the cut-off to
60% dropped the ORR to 14%. Similar results were obtained
with t(4;14) in which the cut-off was set at 30% in the initial
analysis. An ORR of 50% in the isatuximab group was main-
tained across cut-offs ranging from 3% to 40%.
PFS based on the independent response committee assess-
ment was a prespecified subgroup analysis in the high-risk
subgroup. At the time of analysis, 14/24 (583%) high-risk
patients in the isatuximab group and 22/36 (611%) in the
control group had a PFS event. Median PFS (mPFS) in high-
risk patients was longer in the isatuximab group
(75 months) than that in the control group (37 months;
HR, 066; 95% CI, 033–128; Fig 3). Among those treated
with isatuximab, mPFS was lower in high-risk patients
(75 months) than in standard-risk patients (116 months;
Fig 3). However, the benefit of the addition of isatuximab
was similar to that in standard-risk patient in whom the HR
was 062 (95% CI, 042–093; Fig 3). In high-risk patients
with t(4;14), the addition of isatuximab prolonged mPFS
from 28 to 75 months (HR, 049; 95% CI, 019–131). In
high-risk patients with del(17p), the treatment effect of isat-
uximab on PFS was less pronounced (mPFS 91 months in
the isatuximab group vs 74 months in the control group,
HR, 076; 95% CI, 030–192; Fig 3). No significant interac-
tion at the 10% level between treatment groups and cytoge-
netic risk status was observed. Thus, PFS benefit was
observed in both high-risk and standard-risk patients that
received isatuximab in addition to pomalidomide–dexam-
ethasone, but was less pronounced in patients with del(17p).
The sensitivity analysis demonstrated that PFS benefit in
the high-risk subgroup was maintained independent of the
high-risk cytogenetic cut-off definition used. In high-risk
patients with del(17p), mPFS at 5% threshold was
65 months in the isatuximab group and 29 months in the
control group (HR, 077; 95% CI, 035–170). Increasing the
threshold to 50% prolonged the mPFS in both the isatux-
imab group (91 months) as well as in the control group
(74 months; HR, 076; 95% CI, 030–192; Fig 4). A decrease
in mPFS was observed in both groups at 60% cut-off; how-
ever, the isatuximab group had a longer mPFS than that in
the control group across all tested threshold-cut-offs for del
(17p), with HRs between 075 and 088. Similarly, for high-
risk patients with the abnormality t(4;14), prolonged median
PFS was observed with the addition of isatuximab (ranging
from 75 to 81 months) compared with the control group
(28 months). Overall, PFS benefit was maintained across
threshold values ranging from 3% (HR, 049; 95% CI, 019–
131) to 60% (HR, 019; 95% CI, 005–074), favouring the
addition of isatuximab to pomalidomide–dexamethasone
(Fig 4). Sensitivity analyses across threshold values for
translocations may be less meaningful as variations between
patients may be a reflection of the enrichment purity as well
as potential contamination with polyclonal plasma cells.
Consistent with the time to progression (TTP) results
reported in the primary analysis,17 the TTP benefit with isat-
uximab was maintained in high-risk cytogenetic patients
(Figure S1). The HRs for del(17p) were 062 (95% CI, 025–
Table I. Cytogenetic risk in the ITT population at baseline.
Cytogenetic risk in the ITT population at baseline, n (%) Isa–Pd (n = 154) Pd (n = 153)
Standard-risk 103 (669) 78 (510)
High-risk 24 (156) 36 (235)
del(17p) 14 (91) 23 (150)
t(4;14) 12 (78) 14 (92)
t(14;16) 1 (06) 4 (26)
del(17p) and t(4;14) 3 (19) 4 (26)
del(17p) and t(14;16) 0 1 (07)
Unknown/missing 27 (175) 39 (255)
1q21, regardless of other high-risk cytogenetic abnormalities
Gain(1q21), ≥3 copies 76 (494) 52 (340)
Amplification 1q21, ≥4 copies 27 (175) 21 (137)
Isolated 1q21, without other high-risk cytogenetic abnormalities
Gain(1q21), ≥3 copies 56 (364) 29 (190)
Amplification 1q21, ≥4 copies 23 (149) 9 (59)
High-risk cytogenetics was prespecified as ≥1 of: del(17p) 50% cut-off, t(4;14) 30% cut-off, t(14;16) 30% cut-off. The cut-off for gain(1q21) and
amplification 1q21 was 30%.
d, dexamethasone; Isa, isatuximab; ITT, intent-to-treat; P, pomalidomide.
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153) at 5% cut-off and 068 (95% CI, 019–248) at 60%
cut-off (Figure S1). For t(4;14), HRs were 034 (95% CI,
011–104) at 3% cut-off and 014 (95% CI, 003–067) at
60% cut-off; indicating that the TTP benefit with isatuximab
in high-risk cytogenetic patients was independent of the cut-
off definition used.
Table II. Baseline demographic characteristics by risk status.
High-risk CA (n = 60) Standard-risk CA (n = 181)
Isa–Pd (n = 24) Pd (n = 36) Isa–Pd (n = 103) Pd (n = 78)
Age, y
Mean (SD) 680 (81) 656 (108) 665 (93) 647 (85)
Median 675 640 680 660
Min; max 52; 83 41; 86 36; 81 41; 85
Age group (y), n (%)
<65 8 (333) 19 (528) 36 (350) 37 (474)
65–74 9 (375) 6 (167) 47 (456) 32 (410)
≥75 7 (292) 11 (306) 20 (194) 9 (115)
ECOG performance status, n (%)
0 6 (250) 20 (556) 38 (369) 30 (385)
1 14 (583) 10 (278) 54 (524) 41 (526)
2 4 (167) 6 (167) 11 (107) 7 (90)
Geographical region, n (%)
Western Europe 11 (458) 24 (667) 34 (330) 33 (423)
Eastern Europe 4 (167) 3 (83) 20 (194) 13 (167)
North America 1 (42) 1 (28) 5 (49) 2 (26)
Asia 3 (125) 2 (56) 14 (136) 9 (115)
Other countries* 5 (208) 6 (167) 30 (291) 21 (269)
MM subtype at study entry†, n (%)
IgG 15 (625) 27 (750) 71 (689) 52 (667)
IgA 7 (292) 9 (250) 19 (184) 19 (244)
IgM 0 0 2 (19) 0
IgD 0 0 0 0
IgE 0 0 0 0
Kappa light chain only 1 (42) 0 7 (68) 4 (51)
Lambda light chain only 1 (42) 0 4 (39) 3 (38)
Serum LDH, n (%)
≤ULN 13 (542) 22 (611) 73 (709) 55 (705)
>ULN 11 (458) 14 (389) 30 (291) 23 (295)
ISS stage at study entry, n (%)
Stage I 8 (333) 9 (250) 43 (417) 26 (333)
Stage II 8 (333) 15 (417) 36 (350) 29 (372)
Stage III 8 (333) 12 (333) 21 (204) 22 (282)
Unknown 0 0 3 (29) 1 (13)
R-ISS stage at study entry, n (%)
Stage I 0 0 31 (301) 20 (256)
Stage II 16 (667) 24 (667) 64 (621) 51 (654)
Stage III 8 (333) 12 (333) 8 (78) 7 (90)
Previous lines of therapy, median (IQR) 3 (2–6) 3 (2–10) 3 (2–11) 3 (2–7)
Refractory status
Relapsed and refractory‡, n (%) 24 (100) 36 (100) 103 (100) 78 (100)
Primary refractory 0 0 0 0
Relapsed 0 0 0 0
CA, chromosomal abnormalities; d, dexamethasone; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; IQR, interquartile range;
Isa, isatuximab; ISS, international staging system; LDH, lactate dehydrogenase; MM, multiple myeloma; P, pomalidomide; R-ISS, Revised Interna-
tional Staging System; ULN, upper limit of normal.
*Other countries: Australia, New Zealand, Turkey and Russia.
†As per the electronic case report form.
‡Excluding primary refractory.
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Efficacy in patients with gain(1q21)
To evaluate the efficacy of isatuximab addition in patients
with gain(1q21) abnormality, we conducted a retrospective
analysis of plasma cells collected for cytogenetic risk evalua-
tion. FISH testing revealed that 417% (128/307) of the
patients had gain(1q21) abnormality irrespective of other
high-risk cytogenetic abnormalities. Of the randomised pop-
ulation, 261% (80/307) had three copies of gain(1q21) and
156% (48/307) had ≥4 copies (reported later as 1q21 ampli-
fication). More patients had gain(1q21) in the isatuximab
group (494%) than in the control group (340%). Overall,
isatuximab treatment had a positive effect on efficacy in
patients both with and without gain (1q21; Table SI) as well
as in patients with 1q21 amplification (Table SII).
Considering the challenge of interpreting outcomes in the
context of overlapping cytogenetics with other high-risk
abnormalities, we performed a separate subgroup analysis of
patients with isolated gain(1q21), defined as patients with no
other high-risk chromosomal abnormalities [del(17p), t(4;14)
and t(14;16)]. Overall, 277% (85/307) of patients had iso-
lated gain(1q21) with ≥3 copies, with more patients in the
isatuximab group (364% vs 190%). The mPFS was higher
in the isatuximab group than in the control group in
patients with isolated gain(1q21) (112 vs 46 months; HR,
050; 95% CI, 028–088; Table III), and in those without
Fig 1. Overall response rate by cytogenetic cut-off. P values are from the unstratified one-sided Cochran–Mantel–Haenszel test.a ≥ 1 of del(17p),
t(4;14) or t(14;16) at study entry.CR, complete response; d, dexamethasone; IRC, independent review committee; Isa, isatuximab; ORR, overall
response rate; P, pomalidomide; PR, partial response; sCR, stringent complete response; VGPR, very good partial response. [Colour figure can be
viewed at wileyonlinelibrary.com]
Fig 2. Overall response rate sensitivity analysis by cytogenetic cut-off. CI, confidence interval; d, dexamethasone; Isa, isatuximab; NC, not calcula-
ble; P, pomalidomide. [Colour figure can be viewed at wileyonlinelibrary.com]
S. J. Harrison et al.
6 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
gain(1q21) regardless of the presence of other high-risk cyto-
genetic abnormalities (116 vs 98 months; HR, 075; 95%
CI, 040–141; Table SI). Furthermore, the ORR was higher
in the isatuximab group than in the control group for
patients with isolated gain(1q21) (536% vs 276%;
P = 00116), as well as those without gain(1q21) regardless
of the presence of other high-risk cytogenetic abnormalities
(684% vs 435%; P = 00115). Compared with the control
group, the isatuximab group had a higher rate of ≥VGPR
both in patients with isolated gain(1q21) (250% vs 34%;
P = 00070) and without gain(1q21) regardless of the pres-
ence of other high-risk cytogenetic abnormalities (316% vs
109%; P = 00097).
Improved mPFS in the isatuximab group versus control
group was observed both in patients with isolated 1q21
amplification (≥4 copies 1q21; 89 vs 23 months; HR, 055;
95% CI, 021–143; Table III) as well as those with 1q21
amplification, regardless of the presence of other high-risk
cytogenetic abnormalities (89 vs 23 months; HR, 049; 95%
CI, 024–099; Table SII). The addition of isatuximab also
improved ORR [522% vs 111%, P = 00182, isolated 1q21
amplification with ≥4 copies (Table III); 519% vs 95%,
P = 00011, 1q21 amplification regardless of the presence of
other high-risk cytogenetic abnormalities (Table SII)] and
≥VGPR rates [304% vs 0%, P = 00327, isolated 1q21 ampli-
fication with ≥4 copies (Table III); 333% vs 0%, P = 00018,
Fig 3. Progression-free survival in cytogenetic subgroups. a ≥ 1 of del(17p), t(4;14) or t(14;16) at study entry. CI, confidence interval; d, dexam-
ethasone; Isa, isatuximab; P, pomalidomide; PFS, progression-free survival. [Colour figure can be viewed at wileyonlinelibrary.com]
Fig 4. Progression-free survival sensitivity analysis by cytogenetic cut-off. CI, confidence interval; d, dexamethasone; Isa, isatuximab; P, pomalido-
mide; PFS, progression-free survival. [Colour figure can be viewed at wileyonlinelibrary.com]
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1q21 amplification with ≥4 copies, regardless of the presence
of other high-risk cytogenetic abnormalities (Table SII)]
compared with the control group.
Safety
The overall safety with the addition of isatuximab in cytoge-
netic subgroups is summarised in Table IV. The median
duration of treatment was higher in the isatuximab group
than in the control group in both high-risk (32 vs 18 weeks)
and standard-risk (42 vs 31 weeks) subgroups. In patients
treated with isatuximab plus pomalidomide–dexamethasone,
the incidence of grade ≥3 adverse events [AEs; 22 (957%) vs
88 (854%)] and serious adverse events [SAEs; 17 (739%) vs
60 (583%)] was higher in high-risk patients than in
standard-risk patients. This differed from the control group
in which the incidence of grade ≥3 AEs [23 (676%) vs 58
(763%)] and SAEs [17 (500%) vs 47 (618%)] was lower in
high-risk patients than in standard-risk patients. All patients
in the high-risk isatuximab group had treatment-emergent
adverse events (TEAEs) of any grade compared with 941%
in the high-risk control group. However, isatuximab addition
did not increase TEAEs leading to treatment-discontinuation
in the high-risk [two events (87%) isatuximab vs 8 (235%)
control] or standard-risk subgroups [7 events (68%) isatux-
imab vs 6 (79%) control]. These results are consistent with
the findings from the primary analysis, which demonstrated
that isatuximab plus pomalidomide–dexamethasone was well
tolerated, with no increase in treatment discontinuations due
to AEs or the incidence of fatal events during study treat-
ment compared with control group.17
Isatuximab had a manageable safety profile in high-risk
and standard-risk patients (Table IV). In the high-risk sub-
group, analysis from laboratory values reported during study
treatment showed that neutropenia [19 (826%) vs 25
(758%)] and thrombocytopenia [11 (478%) vs 9 (273%)]
occurred more frequently in the isatuximab group than in
the control group. In high-risk patients, granulocyte-colony
stimulating factor (G-CSF) was used in 16 patients (281%)
in the isatuximab group and 21 (368%) in the control
group. A higher incidence of neutropenia with isatuximab
was also observed in standard-risk patients [88 (854%) vs 53
(697%)]. In standard-risk patients, G-CSF was used in 70
patients (391%) in the isatuximab group and 35 (196%) in
the control group.
The most frequent TEAEs in the high-risk isatuximab ver-
sus control group included febrile neutropenia [3 (130%) vs
0] and pneumonia [5 (217%) vs 6 (176%)]. The incidence
rate of both febrile neutropenia and pneumonia in the high-
risk group was generally consistent with the incidence rate in
the standard-risk group. Grade ≥3 infusion reactions
occurred only in the isatuximab group in high-risk and
standard-risk patients: two patients (87%) in the high-risk
and one patient (10%) in the standard-risk group.
Discussion
Recent years have witnessed significant improvements in sur-
vival in MM but such benefits are not always seen in high-
risk patients, whose treatment remains a challenge. Thus, any
new treatment regimen that benefits this group of patients,
identified by specific cytogenetic abnormalities, has the
potential to make a real difference to survival outcomes in
MM.
ICARIA-MM was the first phase 3 study to show positive
outcomes when adding an anti-CD38 antibody (isatuximab)
to pomalidomide–dexamethasone therapy for RRMM in both
high-risk and standard-risk patients.17 In this prespecified
subgroup analysis of patients with high-risk cytogenetics, the
PFS and the ORR benefit with the addition of isatuximab to
pomalidomide–dexamethasone was not only maintained but
was also independent of the cytogenetic cut-off definition
used and also resulted in a manageable safety profile (consis-
tent with data from the overall analysis).
Currently, there are no treatments that can overcome the
poor prognosis of high-risk cytogenetics in MM. IMiDs have
varying effects on high-risk status. While lenalidomide mod-
erately improves TTP in high-risk patients with t(4;14), less
effect was observed in high-risk patients with del(17p).18-20
Previous studies have demonstrated a response benefit of
Table III. Efficacy in the 1q21 subtype without other high-risk chromosomal abnormalities (isolated 1q21).








(n = 9) P value








HR, 050 [028–088] HR, 055 [021–143]
ORR, n (%)[95% CI] 30 (536)[04–07] 8 (276)[01–05] 00116 12 (522)[03–07] 1 (111)[<01–05] 00182
≥VGPR, n (%)[95% CI] 14 (250)[01–04] 1 (34)[<01–02] 00070 7 (304)[01–05] 0[NC] 00327
mPFS, median progression-free survival; CI, confidence interval; ORR, overall response rate; VGPR, very good partial response; Isa, isatuximab;
P, pomalidomide; d, dexamethasone; HR hazard ratio; NC, not calculated.
P values are from the unstratified one-sided Cochran–Mantel–Haenszel test.
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pomalidomide–dexamethasone in patients with del(17p),13,21
while other trials have reported minimal effect on high-risk
patients.22 Proteasome inhibitors, such as bortezomib, carfil-
zomib and ixazomib, have demonstrated the ability to
improve outcomes in high-risk patients when combined with
lenalidomide or pomalidomide, but still, these treatments do
not overcome the poor prognosis of high-risk cytogenetics.23-
25
Targeted therapies against specific cell surface antigens
expressed on MM cells represent an important class of ther-
apy for the treatment of patients with MM. Novel targeted
therapies approved for the treatment of MM include the
monoclonal antibodies, elotuzumab (targets signalling lym-
phocyte activating molecule) and daratumumab (targets
CD38), which exert their effects via direct and indirect
immune-mediated cytotoxicity.11
In triplet combination studies with daratumumab, out-
comes were improved in high-risk cytogenetic patients with
RRMM, but the treatment effect versus standard of care was
variable.26-28 In the updated four-year follow-up of the phase
3 POLLUX study, PFS benefit with daratumumab plus
lenalidomide–dexamethasone was maintained in high-risk
patients (268 vs 83 months), but was lower than the PFS
observed in standard-risk patients (520 vs 186 months).28
Additionally, in the phase 3 CASTOR trial, PFS was
improved in the high-risk group receiving daratumumab plus
bortezomib-dexamethasone (112 vs 72 months). However,
PFS in the high-risk group receiving daratumumab remained
much shorter in comparison to the standard-risk group
receiving daratumumab (112 vs 196 months) while the PFS
for patients receiving bortezomib–dexamethasone remained
nearly the same regardless of risk status [72 (high-risk) vs
70 months (standard-risk)].27
Results from this subgroup analysis indicate that the
treatment benefit with isatuximab is similar both in high-
risk and standard-risk cytogenetic patients; however, it
does not completely overcome the negative prognosis asso-
ciated with high-risk cytogenetics [mPFS 75 (high-risk) vs
116 months (standard-risk)]. Notably, with the addition of
isatuximab, a higher percentage of patients achieved VGPR
in the high-risk group (vs in the control group). Addition-
ally, the PFS and ORR benefit in high-risk cytogenetic
patients treated with isatuximab was maintained irrespec-
tive of the cytogenetic cut-off definition used. This is par-
ticularly important as differences in cytogenetic thresholds
used to determine high-risk status are inconsistently used
and reported in other clinical trials. Although the negative
impact of high-risk status was not overcome, isatuximab
plus pomalidomide–dexamethasone benefits both high-risk
patients and standard-risk patients, and clinical benefit was
obtained in high-risk patients without any emergent safety
issues.
Table IV. Safety in cytogenetic subgroups.
High-risk Standard-risk
Isa-Pd (n = 23) Pd (n = 34) Isa-Pd (n = 103) Pd (n = 76)
Median duration of treatment exposure, wk (range) 320 (13–601) 180 (10–560) 420 (40–767) 313 (20–690)
Any TEAE 23 (100) 32 (941) 102 (990) 75 (987)
Grade ≥3 TEAE 22 (957) 23 (676) 88 (854) 58 (763)
Serious TEAE 17 (739) 17 (500) 60 (583) 47 (618)
TEAE leading to definitive discontinuation 2 (87) 8 (235) 7 (68) 6 (79)
Death due to adverse event 1 (43) 3 (88) 1 (10) 1 (13)
Treatment-related – 1 (29) – 1 (13)
Grade ≥3 events in >5% of patients with Isa-Pd in either subgroup, n (%)
Laboratory abnormalities
Neutropenia 19 (826) 25 (758)* 88 (854) 53 (697)
Thrombocytopenia 11 (478) 9 (273)* 27 (262) 19 (250)
TEAEs
Febrile neutropenia 3 (130) 0 12 (117) 2 (26)
Pneumonia 5 (217) 6 (176) 16 (155) 14 (184)
Influenzal pneumonia 2 (87) 0 0 2 (26)
Urinary tract infection 2 (87) 1 (29) 4 (39) 1 (13)
Lower respiratory tract infection 2 (87) 0 3 (29) 4 (53)
Asthenia 2 (87) 1 (29) 2 (19) 3 (39)
Fatigue 2 (87) 0 3 (29) 0
Infusion reaction 2 (87) 0 1 (10) 0
Pulmonary embolism 2 (87) 0 1 (10) 3 (39)
Vomiting 2 (87) 0 0 0
d, dexamethasone; Isa, isatuximab; P, pomalidomide; TEAE, treatment-emergent adverse event.
*n = 33.
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The positive outcome of isatuximab addition was also
observed in patients with gain(1q21) abnormality, the most
common chromosomal abnormality. Importantly, the mPFS
with isatuximab was 112 months in patients with gain
(1q21), similar to that in the overall study population treated
with isatuximab plus pomalidomide–dexamethasone
(115 months). This is in contrast to the pomalidomide–dex-
amethasone group where patients with gain(1q21) had
shorter mPFS (46 months) than the overall study population
treated with Pd (65 months). This observation is of particu-
lar relevance in light of recent reports of significantly worse
PFS outcomes in patients with gain(1q21) treated with dara-
tumumab.29 The gene coding for complement-inhibitory
protein CD55 is localised to 1q322 and increased expression
of CD55 on myeloma plasma cells has been hypothesised as
a resistance mechanism to daratumumab therapy.29,30 Inter-
estingly, while daratumumab was selected based on its supe-
rior CDC activity,31 the plasma cell kill by isatuximab is
more dependent on ADCC than on CDC.32,33
In conclusion, the results of this subgroup analysis showed
that isatuximab plus pomalidomide–dexamethasone treat-
ment provides a consistent benefit over pomalidomide–dex-
amethasone treatment in patients with RRMM regardless of
cytogenetic risk.
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Table SI. Efficacy in the subgroup with gain(1q21) regard-
less of the presence of other high-risk cytogenetic abnormali-
ties.
Table SII. Efficacy in the subgroup with 1q amplification
with four or more copies 1q21, regardless of the presence of
other high-risk cytogenetic abnormalities.
Fig S1. Time to progression sensitivity analysis by cytoge-
netic cut-off.
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